Gilead Sciences, Inc. (GILD): AI Partnerships Enhancing Biopharmaceutical Advancements
We recently published a list of 10 AI News and Ratings You Should Not Miss. In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against other AI news and ratings you should not miss.
Bernstein Sticks to Its Buy Rating for Gilead Sciences (GILD)
Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of
Cognizant expands AI services for Gilead Sciences
Corporation (NASDAQ: CTSH) has announced the expansion of its partnership with biopharmaceutical company Gilead Sciences (NASDAQ: NASDAQ:GILD), aiming to enhance Gilead's customer service, employee engagement,
Cognizant Expands Partnership with Gilead
Gilead is expected to enhance its efficiency through leveraging Cognizant’s expertise in AI and advanced technology applications. By deploying these solutions across the value chain, Cognizant aims to help Gilead achieve significant benefits through a newly optimized financial framework.
Cognizant Expands Partnership With Gilead Sciences To Enhance Efficiency And AI Integration
Thursday announced that it has expanded its long-standing collaboration with Gilead Sciences (GILD) to enhance cost
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Buying $100 In GILD: If an investor had bought $100 of GILD stock 20 years ago, it would be worth $1,201.60 today based on a ...
Zacks.com on MSN4h
Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report?
Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Gilead Worker Accused of Sex Harassment Advances Defamation Suit
Gilead Sciences Inc. must face a fired employee’s lawsuit alleging its response to a co-worker’s false sexual harassment ...
Breaking Down Gilead Sciences: 22 Analysts Share Their Views
In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of ...
Pharmabiz13h
Cognizant and Gilead expand partnership to drive greater value through advanced technology applications
Cognizant and Gilead expand partnership to drive greater value through advanced technology applications: Teaneck, New Jersey Friday, January 31, 2025, 14:00 Hrs [IST] Cognizant ha ...
Business Wire3d
Gilead Sciences to Release Fourth Quarter & Full Year 2024 Financial Results on Tuesday, February 11, 2025
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...
Gilead Sciences Inc. stock outperforms competitors despite losses on the day
The stock's fall snapped a two-day winning streak.
Gilead Sciences' SWOT analysis: stock outlook shaped by HIV and oncology progress
Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...